RZLT Rezolute Bio: Accounting Value per Share

Graphic logo of Rezolute, Inc. (RZLT)

Rezolute, Inc. (RZLT) generates revenue based on the market launch of targeted therapies, specifically treatments for congenital hyperinsulinism. The price action of the securities on GURU.Markets is currently at 1.03. Active R&D processes and anticipation of late-stage trial results for rare pathologies are driving growth. Furthermore, synergy with scientific institutes is accelerating data collection and the implementation of advanced treatment methods.

Rezolute Inc (RZLT): Share Book Value from 07/04/2022 to 10/27/2026

rezolutebio.com - analytical breakdowns and key metrics (RZLT)

- price and consensus price forecast:
Price Chart Rezolute Corp|RZLT - Price Target Chart
- market capitalization data:
Market Valuation Rezolute, Inc.|RZLT - Aggregate Business Value
- book capitalization data:
Net Assets per Single Share Rezolute|RZLT - Net Asset Value|Market Capitalization to Book Value Ratio rezolutebio.com|RZLT - Aggregate Asset Value
- debt and liquidity data:
Total Debt to Capital Rezolute, Inc.|RZLT - Long-Term Debt to Capital|Short-Term Debt to Equity Rezolute|RZLT - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Rezolute, Inc.
Fundamental company valuation:Rezolute Corp - RZLT
Manufactured products of Rezolute

Rezolute, Inc. (RZLT) operates as a highly specialized biotech firm with a lean staff of leading scientists and clinical trial experts. The metric is calculated by dividing the total net assets by the number of outstanding shares. This metric allows an investor to assess the real value of the business, stripped of market speculation. It serves as an indicator of financial stability and a defensive barrier when evaluating capital. The dynamics of equity per share reflect the actual movement of the company's resources.

Competitors of Rezolute, Inc. (RZLT)

ASND - Net Assets per Single Share|Madrigal Corp (MDGL) - Net Assets per Single Share|CORT - Accounting Value per Share|RYTM (rhythmtx.com) - Book Price of a Share|Net Assets per Single Share Akero AKRO|Share Book Value Metsera, Inc.|MoonLake Pharma (MLTX) - Book Value per Share|Accounting Value of a Share Crinetics Corp (CRNX)|Book Value per Share NAMS (NewAmsterdam Pharma)|soleno.life - Book Value per Share|Net Assets per Single Share Amicus Therapeutics, Inc. (FOLD)|ETNB: Accounting Value of a Share|AGIO (Agios Pharmaceuticals Inc) - Net Assets per Single Share|Structure Corp (GPCR) - Accounting Value per Share|MDXG (MiMedx Group, Inc.) - Book Value per Share|Book Value per Share lexpharma.com (LXRX)|MBX Biosciences (MBX) - Accounting Value per Share|Accounting Value of a Share ALT (Altimmune Inc)|Aardvark Therapeutics Corp - Net Assets per Single Share|Accounting Value per Share Sagimet Biosciences Inc SGMT|BIOA (BioAge Labs, Inc.) - Book Value per Share|biomeafusion.com (BMEA) - Net Asset Value per Share|QNCX - Accounting Value per Share|Fractyl Health Inc. (GUTS) - Book Price of a Share|VTVT (vTv Therapeutics, Inc.) - Book Value per Share|Book Value per Share Agape ATP Corp.|Book Value per Share Pluri Inc. (PLUR)|Net Assets per Single Share SYBX (synlogictx.com)|LPCN: Net Assets per Single Share|Matinas BioPharma Holdings, Inc. - Net Asset Value per Share|SPRB - Net Assets per Single Share|GLTO - Net Assets per Single Share|Carmell Corporation - Book Value per Share|LUMO (lumos-pharma.com) - Net Assets per Share|ONVO: Net Assets per Single Share|Net Assets per Share RDUS